2023 was a breakthrough year for cell and gene therapies. The field saw a record number of FDA approvals, as other promising therapies in a broad range of therapeutic areas progressed through the pipeline. 2024 looks to be another important year with up to 17 new therapies poised for regulatory approval. “This is just…
Featured Content
The days of siloed approaches to chronic conditions such as HIV are over
Taken from PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on the HTA decision analysis framework in Denmark. Buy The Pharma Legal Handbook: Market Access & HTA – Denmark here for £359. Which are the health technology assessment (HTA) evaluation bodies and their responsibilities in…
Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine. After generating sales of USD 18.4 billion in 2022, demand for the company’s Spikevax shot, still its only commercialized product to date, have fallen drastically.…
In Conversation
Peter Arlett – Head of Data Analytics and Methods, European Medicines Agency (EMA)
We are in the business of excellent clinical evidence. EMA wants to partner with stakeholders, including those from industry, to drive up the quality of evidence that supports the decisions of regulators, HTA bodies, and payers
Shinobu Uzu – Senior Executive Director, PMDA, Japan
International pharmaceutical companies [should] not only look at Japan as a single country, but also as the gateway to Asia
Andrew Ng – Partner, Head of Healthcare, Private Equity, VMS Group
By focusing on developing exceptional products and leveraging strategic partnerships with vendors and CXOs, entrepreneurs can optimize their resources and navigate the intricacies of the Chinese market more effectively
Sarah McMullen, Country Director, FDA India Office
As the saying goes – “a rising tide lifts all boats”, and we would expect that universal implementation of GMPs would buoy product quality among those firms in compliance
Dan Staner – VP, General Manager Germany & Switzerland and Head of the Middle East Region, Moderna
Our culture is about entrepreneurship, risk-taking, bold moves, and disruption
Cynthia Xin Wang – Head of Business Development Asia, Servier
Cultural alignment and trust are paramount considerations when exploring collaborations or investments in the Chinese biotech sector
Basel Al-Qahtani – General Manager, Boston Scientific Saudi Arabia
We are dedicated to helping the country achieve its healthcare transformation objectives by bringing innovative technologies to the market, leveraging our global expertise, and partnering with key healthcare institutions
Mitchell Warren – Executive Director, AVAC
We now have the scientific tools to end the HIV epidemic; the challenge lies in delivery
Maria Mota – Executive Director, iMM
We are a creative institution and should safeguard researchers in their work and in the development of their own ideas, but at the same time we should be actively contributing to resolving health issues
In Case You Missed It
InFigures
Apart from a maturing regulatory environment and the expansion of healthcare coverage across the region, a number of other factors are contributing to the evolution of the MEA pharma market. Results from the second wave of a PhRMA-commisioned IQVIA market access study covering Saudi Arabia (KSA), UAE, Kuwait, Lebanon, Jordan, Egypt, Algeria, Morocco, Tunisia and…
Latin America will be the world’s fastest growing region for pharmaceuticals up to 2027, with a stunning expected compound annual growth rate of 22 percent, according to recent reporting from IQVIA. The Indian subcontinent can also expect sizeable growth over the next three years, although the US, Europe, and East Asia will remain the largest…
The top 10 pharma companies in Portugal ranked by sales value in both the hospital and pharmacy markets. These charts are from IQVIA and are based on a moving annual total up to October 2023. Household Big Pharma names like Janssen (recently rebranded as Johnson & Johnson Innovative Medicines), Roche, MSD, and Novartis dominate the…
The top 10 Indian pharma companies ranked by market capitalization as of June 2023, compiled by Global Data. Way out in front is Sun Pharma, followed by Dr Reddy’s and Cipla. Made with Visme Infographic Maker
